Crizotinib-induced abnormal signal processing in the retina

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Ishii, Toshiyuki ^a   Iwasawa, Shunichiro ^b   Kurimoto, Ryota ^b   Maeda, Akemi ^a,c   Takiguchi, Yuichi ^b   Kaneda, Makoto ^a   Barnes, Steven ^d  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c Tokyo Medical Care and Welfare Vocational School   (Japan)

^d DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; MESSENGER RNA; CARBAZOLE DERIVATIVE; ONCOPROTEIN; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; ROS1 PROTEIN, MOUSE; SCATTER FACTOR RECEPTOR;

ALK GENE; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; FIRING RATE; GENE; GENE EXPRESSION; MALE; MET GENE; MOUSE; NONHUMAN; PHOTOSTIMULATION; RETINA; RETINA GANGLION CELL; ROS1 GENE; VISUAL DISORDER; ANIMAL; DRUG EFFECTS; GENETICS; IN VITRO STUDY; METABOLISM;

ANIMALS; CARBAZOLES; FEMALE; IN VITRO TECHNIQUES; MALE; MICE; PIPERIDINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RETINA; RETINAL GANGLION CELLS;

EID: 84943158576     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0135521     Document Type: Article

References (31)

1. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. The New England journal of medicine 362: 2380-2388. doi: 10.1056/NEJMoa0909530 PMID: 20573926
2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan E.H., Hirsh V., Thongprasert S, et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. The New England journal of medicine 353:123-132. PMID: 16014882
3. Segaert S, Van Cutsem E (2005) Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Annals of oncology 16: 1425-1433. PMID: 16012181
4. Miller VA, Hirsh V, Cadranel J., Chen YM, Park K, Kim SW, et al. (2012) Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. The Lancet Oncology 13: 528-538. doi: 10.1016/S1470-2045(12)70087-6 PMID: 22452896
5. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, et al. (2007) Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cis-platin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Annals of oncology 18:317-323. PMID: 17079694
6. Paz-Ares L.G., de Marinis F, Dediu M, Thomas M., Pujol JL, Bidoli P, et al. (2013) PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. Journal of clinical oncology 31: 2895-2902. doi: 10.1200/JCO.2012.47.1102 PMID: 23835707
7. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. The Lancet Oncology 11:121-128. doi: 10.1016/S1470-2045(09)70364-X PMID: 20022809
8. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. The Lancet Oncology 12: 735-742. doi: 10.1016/S1470-2045(11)70184-X PMID: 21783417
9. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. The New England journal of medicine 363:1693-1703. doi: 10.1056/NEJMoa1006448 PMID: 20979469
10. Gambacorti-Passerini C., Messa C, Pogliani E.M. (2011) Crizotinib in anaplastic large-cell lymphoma. The New England journal of medicine 364: 775-776. doi: 10.1056/NEJMc1013224 PMID: 21345110
11. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. (2007) Identification of the transforming EML4-ALKfusion gene in non-small-cell lung cancer. Nature 448: 561-566. PMID: 17625570
12. Mano H (2008) Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer science 99: 2349-2355. doi: 10.1111/j.1349-7006.2008.00972.x PMID: 19032370
13. Soda M, Takada S, Takeuchi K., Choi YL, Enomoto M, Ueno T, et al (2008) A mouse model for EML4-ALK-positive lung cancer. Proceedings of the National Academy of Sciences of the United States of America 105:19893-19897. doi: 10.1073/pnas.0805381105 PMID: 19064915
14. Ou SH, Kwak EL, Siwak-Tapp C, Dy J, Bergethon K, Clark JW, et al. (2011) Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. Journal of thoracic oncology 6: 942-946. doi: 10.1097/JTO.0b013e31821528d3 PMID: 21623265
15. Bergethon K, Shaw AT, Ou S.H., Katayama R., Lovly CM, McDonald NT, et al. (2012) ROS1 rearrangements define a unique molecular class of lung cancers. Journal of clinical oncology 30: 863-870. doi: 10.1200/JCO.2011.35.6345 PMID: 22215748
16. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, et al. (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. The Lancet Oncology 13:1011-1019. doi: 10.1016/S1470-2045(12)70344-3 PMID: 22954507
17. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. The New England journal of medicine 368: 2385-2394. doi: 10.1056/NEJMoa1214886 PMID: 23724913
18. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. The New England journal of medicine 371: 2167-2177. doi: 10.1056/NE JMoa1408440 PMID: 25470694
19. Shaw AT, Ou SH, Bang Y.J., Camidge DR, Solomon BJ, Salgia R, et al (2014) Crizotinib in ROS1-rearranged non-small-cell lung cancer. The New England journal of medicine 371:1963-1971. doi: 10.1056/NEJMoa1406766 PMID: 25264305
20. Gadgeel SM, Gandhi L, Riely G.J., Chiappori AA, West HL, Azada MC, et al. (2014) Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistantALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. The Lancet Oncology 15:1119-1128. doi: 10.1016/S1470-2045(14)70362-6 PMID: 25153538
21. Seto T, Kiura K, Nishio M, Nakagawa K, Maemondo M, Inoue A, et al. (2013) CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. The Lancet Oncology 14: 590-598. doi: 10.1016/S1470-2045(13)70142-6 PMID: 23639470
22. Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Vas Laethem JL, et al. (2013) Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. The Lancet Oncology 14: 55-63. doi: 10.1016/S1470-2045(12)70490-4 PMID: 23182627
23. Kaneda M, Ishii T, Hosoya T. (2008) Pathway-dependent modulation by P2-purinoceptors in the mouse retina. The European journal of neuroscience 28:128-136. doi: 10.1111/j.1460-9568.2008.06317.x PMID: 18616561
24. Meister M, Pine J, Baylor D.A. (1994) Multi-neuronal signals from the retina: acquisition and analysis. Journal of neuroscience methods 51:95-106. PMID: 8189755
25. Phizer Inc. (2012) Crizotinib Interview form, 3rd edition.
26. Adrian ED, Zotterman Y. (1926) The impulses produced by sensory nerve-endings: Part II. The response of a Single End-Organ. The Journal of physiology 61:151-171. PMID: 16993780
27. Rieke F WD, de Ruytervan Steveninck R, Bialek W (1997) Spikes: exploring the neural code. Cambridge, MA: MIT press.
28. Perez CA, Velez M, Raez LE, Santos ES (2014) Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation. Lung cancer 84:110-115. doi: 10.1016/j.lungcan.2014.02.001 PMID: 24598368
29. Liu CN, Mathialagan N, Lappin P., Fortner J, Somps C, Seitis G, et al. (2015) Crizotinib reduces the rate of dark adaptation in the rat retina independent of ALK inhibition. Toxicological sciences 143:116-125. doi: 10.1093/toxsci/kfu213 PMID: 25326243
30. Kodama T, Tsukaguchi T, Satoh Y, Yoshida M., Watanabe Y, Kondoh O, et al (2014) Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. Molecular cancer therapeutics 13: 2910-2918. doi: 10.1158/1535-7163.MCT-14-0274 PMID: 25349307
31. Chugai Pharmaceutical Co. Ltd. (2014) Alectinib Interview form, 2nd edition.